Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma.
Christos SachpekidisAnnette Kopp-SchneiderLeyun PanDimitrios PapamichailUwe HaberkornJessica C HasselAntonia Dimitrakopoulou-StraussPublished in: European journal of nuclear medicine and molecular imaging (2020)
PET/CT-based response of metastatic melanoma to PD-1 blockade after application of the recently proposed PERCIMT criteria is significantly correlated with PFS. This highlights the potential ability of [18F]FDG PET/CT for early stratification of response to anti-PD-1 agents, a finding with possible significant clinical and financial implications. Further studies including larger numbers of patients are necessary to validate these results.